First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors

NCT04564417 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Solid Tumors

Interventions

BIOLOGICAL: W0180
DRUG: Pembrolizumab

Sponsor

Pierre Fabre Medicament